A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers

類似資料

• A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers
  著者:: Leong, Joel, 等
  出版事項: (2014)
• Spiroindolone KAE609 for Falciparum and Vivax Malaria
  著者:: White, Nicholas J., 等
  出版事項: (2014)
• Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor
  著者:: Goldgof, Gregory M., 等
  出版事項: (2016)
• Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model
  著者:: Lakshminarayana, Suresh B., 等
  出版事項: (2015)
• The Spiroindolone KAE609 Does Not Induce Dormant Ring Stages in Plasmodium falciparum Parasites
  著者:: Chavchich, Marina, 等
  出版事項: (2016)